2nd Next-Generation Conjugate Summit

Paid

With numerous next-generation conjugate companies recently receiving their INDs to enter the clinic including Avidity Biosciences and Dyne Therapeutics and many more following closely in their footsteps, conjugate drugs comprising of novel payloads and targeting formats are being thrust centre stage within the bioconjugate world.

21-23 February 2023

Healthcare

Protein Degraders and Molecular Glues – Part 2

Paid

A new generation of molecules are being developed to disrupt protein-protein interactions and to hijack the cell’s natural machinery for targeted protein degradation. Proteolysis-targeting chimeras (PROTACs), molecular glues, and other modalities are utilizing the ubiquitin-proteasome, lysosome, and autophagy systems to seek out previously “undrugg

27-28 September 2023

Healthcare